Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Amifostine for Paclitaxel-Induced Peripheral Neuropathy
NCT00078845Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2004
- Primary completion
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amifostine in peripheral neuropathy, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Neurotoxicity secondary to cancer therapy as measured by FACT-GOG-NTX scale at 12 weeks. Started May 2004; status: completed.
02
Drugs
amifostine
03
Conditions
peripheral neuropathy
Beyond the preview
Go deeper on NCT00078845.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00078845.